165 filings
Page 4 of 9
8-K
kel8ib6o
25 Feb 21
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
4:11pm
8-K
ykjslnk
2 Feb 21
Departure of Directors or Certain Officers
4:39pm
8-K
gpj3y50go12wlim29ql
5 Jan 21
Results of Operations and Financial Condition
8:12am
8-K
vbth3
29 Dec 20
Securities Purchase Agreement
8:11am
8-K
g1aifi9vu utl
22 Dec 20
Securities Purchase Agreement
8:16am
8-K
j650fmze35i0
9 Dec 20
Capital on Demandâ„¢ Sales Agreement
5:11pm
8-K
i031 hy79y9cj4845r
10 Nov 20
TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:15pm
8-K
fgb2objj wuft
21 Sep 20
TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results
8:30am
8-K
m71tqm
31 Aug 20
Securities Purchase Agreement
8:13am
8-K
guh29kg thftv9ad
27 Aug 20
Securities Purchase Agreement
8:18am
8-K
xdyjlxfowc35tkt21k
5 Aug 20
TRACON Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
4:12pm
8-K
42ff kx0rurhvjzor02t
11 Jun 20
Submission of Matters to a Vote of Security Holders
4:13pm
8-K
0gsvdx
14 May 20
Other Events
8:40am
8-K
yoq84250l1r
13 May 20
TRACON Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
4:12pm
8-K
3jspf9 afxiys2
4 May 20
Entry into a Material Definitive Agreement
4:37pm
8-K
f5y19b9
24 Apr 20
TRACON Pharmaceuticals Retains Global Rights to TRC253 Following Completion of a Phase 1/2 Trial
8:30am
8-K
s6w9i j9t0l9noelo
15 Apr 20
Entry into a Material Definitive Agreement
4:55pm
8-K
6p47eok6b64ml
19 Mar 20
TRACON Pharmaceuticals Announces Appointment of Saundra Pelletier to Board of Directors
8:30am
8-K
bzljz0a3co45xa1oy0nx
13 Mar 20
Departure of Directors or Certain Officers
4:09pm
8-K
fx3cwmv4
10 Mar 20
Santen and TRACON Discontinue Development of DE-122
12:00am